MORGAN STANLEY PLC/PUT/VERTEX PHARMACEUTICALS/400/0.01/20.12.24 | Delayed Börse Stuttgart 04:35:20 2024-07-05 EDT | ||
| 0.108 EUR | +3.85% |
|
| Current month | -7.96% | ||
| 1 month | -18.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.108 | +3.85% |
| 24-07-04 | 0.104 | -7.14% |
| 24-07-03 | 0.112 | +6.67% |
| 24-07-02 | 0.105 | -6.25% |
| 24-07-01 | 0.112 | -0.88% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 04:35 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME6701 |
| ISIN | DE000ME67011 |
| Date issued | 2024-01-02 |
| Strike | 400 $ |
| Maturity | 2024-12-20 (169 Days) |
| Parity | 100 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.39 € |
|---|---|
| Lowest since issue | 0.103 € |
| Spread | 0.02 € |
| Spread % | 15.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
